BLRX Reports $20.9M Cash, $0.00 EPS, Announces Phase 1/2a GLIX1 GBM Trial Start, Patent Allowed Until 2040, Motixafortide Pancreatic Trial Accelerated
BioLineRX Ltd · Now $3.48
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS